Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic disease products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brands; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer's Dividend Streak Stalls at $0.43 as Peers Keep Raising
Pfizer's decade-long streak of annual dividend increases has stalled, with its quarterly payout holding at $0.43 through the September 1, 2026 payment after the January 2026 ex-dividend date matched the prior four quarters instead of rising. The 6.20% yield remains covered by reaffirmed 2026 adjusted diluted EPS guidance of $2.80 to $3.00 against a run-rate $1.72 annual payout, and Q1 2026 adjusted EPS of $0.75 beat consensus for a fifth consecutive quarter above estimates. Cash outflow is real, with $2.4 billion in dividends paid in Q1 alone and $9.8 billion for full-year 2025, while Pfizer completed no buybacks in 2025 and anticipates none in 2026 despite $3.3 billion of unused authorization. On the August 4, 2026 call, incoming interim CFO Cecile Guegan said Pfizer would keep maintaining and over the long term growing the dividend, and Chairman and CEO Albert Bourla said the dividend will be maintained and eventually start growing again after the loss-of-exclusivity period. Peers have not frozen their payouts: Merck raised its quarterly from $0.81 to $0.85 starting with the December 2025 ex-date, and Bristol-Myers Squibb nudged its payout from $0.62 to $0.63 with the January 2026 ex-date. The pressure behind the pause is visible in the mix, with Comirnaty down 59% and Paxlovid down 62% in Q1 2026 and roughly $1.5 billion in additional generic and biosimilar headwind guided for the year, partly offset by launched and acquired products growing 22% operationally and Vyndamax exclusivity now running to June 2031.
Merck Wins Positive EU CHMP Opinion for KEYTRUDA Plus Padcev in Resectable Muscle-Invasive Bladder Cancer
Merck announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of KEYTRUDA, the company's anti-PD-1 therapy, in combination with Padcev as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable muscle-invasive bladder cancer. The recommendation, which also includes KEYTRUDA SC, known as KEYTRUDA QLEX in the U.S., will now be reviewed by the European Commission for marketing authorization in the European Union, Iceland, Liechtenstein and Norway, with a final decision expected by the fourth quarter of 2026. The opinion is based on results from the Phase 3 KEYNOTE-B15 trial, also known as EV-304, conducted in collaboration with Pfizer and Astellas, in which the perioperative regimen reduced the risk of event-free survival events by 47% (HR=0.53) and the risk of death by 35% (HR=0.65) versus neoadjuvant chemotherapy and surgery in cisplatin-eligible patients, while pathologic complete response reached 55.8% versus 32.5%. If approved, KEYTRUDA plus Padcev would become the first and only PD-1 inhibitor plus antibody-drug conjugate regimen in the European Union for patients with MIBC regardless of cisplatin eligibility. In June 2026, the European Commission approved the combination for cisplatin-ineligible adults with resectable MIBC based on the Phase 3 KEYNOTE-905 trial, and in July 2026 the U.S. Food and Drug Administration approved it for adults with MIBC regardless of cisplatin eligibility based on KEYNOTE-B15.
Vaxcyte Hires Pfizer and Teva Veterans, Moves VAX-31 Phase 3 Data to October
Vaxcyte announced two C-suite hires on September 3 and narrowed the timeline for its most important catalyst, saying it now expects topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial by the end of October rather than sometime in the fourth quarter. Luis Jodar joins as Chief Medical Officer after 17 years at Pfizer, where he was Chief Medical Officer for Vaccines and Infectious Diseases and helped lead clinical development and medical affairs for Prevnar 13 and Prevnar 20, the pneumococcal vaccines VAX-31 is trying to displace. David McAvoy joins as Chief Legal Officer from Teva Pharmaceutical, where he ran a 235-person legal, compliance and government affairs organization as Executive Vice President and Chief Legal Officer, and previously served as General Counsel of Endocyte through its $2.1 billion acquisition by Novartis and spent 27 years at Eli Lilly. The OPUS-1 trial alone dosed 4,049 participants in a head-to-head comparison against Prevnar 20 and Capvaxive, part of a broader Phase 3 program that has dosed 6,191 adults in total, roughly 3,500 of them with VAX-31, and Vaxcyte held about $2.5 billion in cash, cash equivalents and investments as of June 30, 2026. The trial measures safety, tolerability and immunogenicity against Prevnar 20 and Capvaxive rather than a fresh efficacy claim, so the near-term thesis rests on VAX-31 clearing a noninferiority bar, and the company still has no approved product or product revenue, with OPUS-2 and OPUS-3 data and the VAX-31 infant Phase 2 study not expected until the first half of 2027 and the VAX-A1 Group A Strep candidate not guided to topline data until the second half of 2027.
Pfizer Licenses CD228-Targeting ADC to Medicus Pharma in Co-Development Deal
Pfizer has signed a co-development and license deal with Medicus Pharma for an early clinical-stage CD228-targeting antibody-drug conjugate. The agreement grants Medicus exclusive global rights to develop and commercialize the CD228V candidate across multiple human disease areas, while Pfizer retains economic participation through financial milestones, royalties and ongoing involvement in the CD228V development program. Pfizer, a US-based pharmaceuticals group with a market value of about $158.0 billion, is handing Medicus day-to-day development and commercialization duties while keeping the patents, milestone rights and royalties, limiting its upfront spend on an early clinical asset and preserving a cut of future upside across indications. The next real test comes when Medicus moves CD228V toward a first pivotal trial and Pfizer must decide whether to exercise its option to fund later-stage development, a decision point that, alongside any detail shared at events such as the Morgan Stanley Global Healthcare Conference on 14 September 2026, will show how important Pfizer sees the asset within its oncology plans.
Pfizer and Valneva Lyme Vaccine PF-07307405 Enters EMA Review
The European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the experimental Lyme disease vaccine candidate from Pfizer and French biotech Valneva, and will now begin its official review. The filing rests on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older in high-incidence Lyme disease locations across the US, Canada, and Europe, which reported efficacy of over 70% in reducing confirmed Lyme disease cases with no safety issues detected. The statistical picture was less clean than the headline number: the first prespecified analysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%, while a second prespecified analysis showed 74.8% efficacy and did meet that threshold. Under the 2020 partnership and license agreement, Pfizer holds exclusive rights to produce and commercialize the vaccine if approved, with Valneva benefiting as development partner; Valneva says PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development. Pfizer shares were essentially flat on the news, and hedge fund ownership stood at 83 funds in the second quarter of 2026, unchanged from the first quarter, while Valneva's hedge fund exposure rose to 4 funds from 1. MAA validation means the application meets the standards for the EMA to begin evaluating it, not that approval is near or guaranteed, and formal reviews of this nature often take many months to complete.
IP Group H1 NAV Rises 3.2% as Pfizer Royalty Lifts Valuation
IP Group reported a 3.2% rise in net asset value per share to 114p in the first half, taking total NAV above £1 billion, with Chief Executive Greg Smith saying NAV per share had since reached approximately 117p as of Sept. 11, mainly on a higher valuation of its listed Oxford Nanopore holding. The science and technology investor generated £69 million of cash proceeds in the half, exceeding the proceeds recorded for the whole of 2025, and a further £17 million received after the period end brought year-to-date proceeds to about £86 million and total proceeds since the start of 2025 to £154 million, against a target of £250 million of realizations by the end of 2027. The largest contributor to the half-year valuation gain was IP Group's royalty interest in Pfizer's obesity treatment programs, whose carrying value rose by £27 million to just over £150 million after Pfizer's berobenatide and amylin combination advanced into a Phase IIb clinical trial, lifting the estimated probability for the combination therapy from 25% to 39%. Portfolio companies raised more than £500 million from third-party investors during the half, with IP Group contributing approximately 5% of that capital, and Oxford Nanopore reported £117 million of revenue, 12% constant-currency growth, a 400-basis-point gross margin improvement to 62%, and an adjusted EBITDA loss that more than halved to just over £22 million. The company ended June with £239 million to £240 million of gross cash and deposits, and Smith said around £50 million of realization proceeds was available for future shareholder returns under the board-approved capital allocation policy.
Pfizer Guides 2026 Revenue of $60.5B-$62.5B as Patent Cliff Looms
Pfizer is guiding 2026 total revenues to between $60.5 billion and $62.5 billion, a slight decline from 2025 revenues of $62.6 billion, as it absorbs the loss of exclusivity on key products and lower COVID-19 sales. The company expects the patent cliff to hurt sales by approximately $1.1 billion in 2026, with Eliquis, Ibrance, Xeljanz and Xtandi facing expirations during the 2026-2030 period. Adjusted earnings per share for 2026 are guided to $2.80-$3.00, down from 2025 EPS of $3.22, reflecting the dilutive impact of the 3SBio and Metsera deals, lower COVID revenues and higher taxes. Pfizer is leaning on recently launched and acquired products, which posted double-digit growth in both the first and second quarters of 2026, plus a high single-digit revenue CAGR target over five years starting from year-end 2028, to return to growth from 2029 onward. The Zacks Consensus Estimate for 2026 earnings per share has risen from $2.96 to $2.98 and for 2027 from $2.86 to $2.94 over the past 60 days, while Pfizer shares trade at 9.40 forward earnings versus 17.86 for the industry.
AstraZeneca's Etcamah Fails Phase 3 SERENA-4 Breast Cancer Trial
AstraZeneca's recently approved Etcamah, also known as camizestrant, failed in a phase 3 trial as a first-line treatment in combination with Pfizer's Ibrance, or palbociclib, for HR+, HER2- breast cancer. Results from the SERENA-4 trial showed the combination did not improve progression-free survival versus Ibrance plus the aromatase inhibitor Arimidex, or anastrozole, with statistical significance. The trial enrolled about 1,400 individuals with no systemic treatment for metastatic disease. Etcamah is also being tested in two other phase 3 trials, CAMBRIA-1 and CAMBRIA-2, which have enrolled about 10,000 patients examining the drug in individuals with intermediate and high risk of recurrence in the adjuvant setting as monotherapy, in combination with CDK4/6 inhibitors, and following CDK4/6 inhibitor treatment. Etcamah received accelerated approval earlier in September for those with breast cancer who possess an estrogen receptor-1 mutation, which can be discovered during aromatase inhibitor and CDK 4/6 inhibitor therapy.
Novo Nordisk's Oral Wegovy Moves Closer to China Approval
Novo Nordisk has moved one step closer to bringing its oral Wegovy treatment to China after the country's drug regulator accepted the company's marketing application, opening a potential route into a market where GLP-1 weight-management sales could reach 30 billion yuan, or about $4.46 billion, within five to seven years, according to J.P. Morgan's head of China healthcare research, Yang Huang. The filing is an early regulatory milestone, not a final approval, and Novo has declined to provide a timeline for a decision. An oral version could help Novo reach patients who avoid injections, and the pill has already been approved in the United States and Britain, with a US launch earlier in 2026. However, Eli Lilly submitted its Chinese application for oral orforglipron at the end of 2025 and could launch as early as 2026, while Novo, Lilly, Pfizer, and Innovent Biologics already compete with injectable GLP-1 products in China. The 30-billion-yuan projection is an analyst forecast for the entire market, not an estimate of Wegovy's future sales, and the treatment's commercial contribution will depend on regulatory approval and competition in a crowded field.
Novartis India buys Pfizer hypertension brands for $132m
Novartis India has agreed to pay Rs12.5bn ($132m) to acquire the Minipres and Minipress trademarks in India, along with associated intellectual property rights, from Pfizer and Pfizer Products. The deal adds an established hypertension brand to Novartis' cardiovascular range and was cleared by Novartis India's board, after which the company signed an asset purchase agreement and trademark assignment deeds with the two Pfizer entities. The transaction covers trademarks registered in India, with signing and closing occurring simultaneously, and is not a related-party transaction. The agreement coincides with Pfizer's withdrawal of Minipress XL in India, as Pfizer will stop marketing, distributing, and selling the product from 7 September after Pfizer USA decided to end its manufacture. Minipress XL, containing prazosin, is used mainly to treat hypertension and manage urinary symptoms linked to benign prostatic hyperplasia, giving Novartis India a brand spanning both cardiovascular treatment and BPH management. Citing IQVIA data, Novartis India said Minipress XL recorded revenue of Rs2.28bn in the 12 months to July 2026, growing at a compound annual growth rate of 6.3% over the past four years, below the 9% recorded by the wider category. The payment is substantial for Novartis India, which has been building its portfolio through selective brand purchases, and comes after private equity company ChrysCapital agreed in December 2025 to acquire a controlling stake in Novartis India.
RFK Jr. probes whether U.S. troops died from COVID vaccines
Health Secretary Robert F. Kennedy Jr. and Defense Secretary Pete Hegseth are investigating whether U.S. troops died from COVID-19 vaccines, with an Army doctor testifying that she is examining 2,544 unverified deaths reported to HHS's Vaccine Adverse Event Reporting System. Army doctor Theresa Long, who is board certified in aerospace medicine, said during a Virginia federal court hearing that she is aware of 28 individuals who died due to COVID vaccinations but was barred from sharing further details. The deaths under scrutiny are linked to mRNA vaccines from Pfizer/BioNTech and Moderna. Long, who began her duties at the Defense Department 10 days before she was set to retire, expects to finish her work within a year. The Pentagon said it has nothing to announce at this time, referring to a statement on reinstating service members discharged during the Biden administration for refusing the shots.
Pfizer's pipeline strategy is centered on obesity and oncology as the company seeks to revive growth after declining COVID-19 product revenues and upcoming patent expirations. As of Aug. 4, 2026, Pfizer had 95 pipeline programs, with the most important assets concentrated in these two areas. The key emerging asset is berobenatide, a monthly GLP-1 receptor agonist from the Metsera acquisition, which is in phase III for chronic weight management and targets potential approvals starting in 2028. In oncology, Pfizer is advancing late-stage candidates such as atirmociclib, sigvotatug vedotin, and mevrometostat, and has initiated pivotal phase III studies for PF-08634404, a dual PD-1/VEGF inhibitor in-licensed from 3SBio. Pfizer stock has risen 16.6% so far this year, and the Zacks Consensus Estimate for 2026 EPS has increased from $2.96 to $2.98 over the past 30 days.
Trump unveils drug-pricing deals with CSL, Astellas, and other biotechs
President Donald Trump introduced a new set of drug-pricing deals with global pharmaceutical companies and smaller biotechs on Monday, advancing efforts to cut healthcare costs for American consumers. Deals were signed with Astellas, BeOne Medicines, CSL, BridgeBio, Sun Pharmaceutical, and UCB SA, Trump said in an Oval Office event with executives, according to Reuters. These companies have offered drugs to state Medicaid programs at most-favored-nation prices, which Trump described as a tremendous discount that should bring down medical costs. Israel's Teva, which also attended, said it is still in discussions with the administration on a potential agreement. The number of drugs covered and the discounts remain unclear, as the White House did not release details and some companies described terms as private. The deals follow earlier agreements with 17 of the world's largest drugmakers, including Pfizer, Eli Lilly, and Novo Nordisk, which agreed to cut prices for federal health programs and sell some medicines directly to patients through a Trump-branded website in return for tariff relief.
Pfizer Reaches Confidential Settlement in Depo-Provera Lawsuits
Pfizer has reached a confidential settlement covering federal lawsuits over its Depo-Provera contraceptive and alleged intracranial meningioma risk, addressing more than 6,000 cases with financial terms undisclosed and no admission of liability. The resolution closes a multi-year legal overhang tied to Depo-Provera, bringing clarity to a significant product liability dispute. For investors, this settlement reduces one legal overhang but leaves broader concerns about profit margins, debt levels, and the upcoming patent cliff on major drugs. The investment story for Pfizer still leans more heavily on its obesity, oncology, and vaccine pipeline. The key thing to watch now is how Pfizer quantifies any settlement-related charges in upcoming filings and earnings, and whether management updates its longer-term margin and earnings guidance once the Depo-Provera program is fully implemented.
Pfizer's Oncology Growth Led by Padcev and Pipeline
Pfizer's oncology segment, which accounts for about 27% of total revenues, posted a 3% increase to $4.17 billion in the second quarter of 2026, driven by strong sales of Padcev, Lorbrena, and Braftovi/Mektovi. Padcev sales climbed 23% to $667 million, benefiting from market share gains in first-line metastatic urothelial cancer and the recent FDA approval for muscle-invasive bladder cancer, which expanded its addressable market to more than 42,000 U.S. patients. The company is also advancing its pipeline, including PF-08634404, a dual PD-1/VEGF inhibitor in-licensed from 3SBio, with pivotal phase III studies in colorectal and lung cancers. Pfizer expects to have eight or more blockbuster oncology medicines by 2030, while competitors like J&J, AstraZeneca, and Merck also report strong oncology growth. Pfizer's stock trades at 9.48 forward earnings, below the industry's 18.71, and the Zacks Consensus Estimate for 2026 EPS has risen to $2.98.
Alnylam presents new Amvuttra and zilebesiran data at ESC Congress
Alnylam Pharmaceuticals presented new analyses at the European Society of Cardiology Congress in Munich supporting the use of Amvuttra across a range of transthyretin amyloidosis patients, including those already on Pfizer's tafamidis, and reported encouraging subgroup findings for its experimental hypertension drug zilebesiran. In the Phase 3 HELIOS-B study, 259 of the 654 treated patients were taking tafamidis at baseline, and Amvuttra's effect on the composite of death and recurrent cardiovascular events appeared consistent regardless of tafamidis use. Patients on Amvuttra also showed better preservation of walking ability and a 25% less deterioration in a composite measure of physical and mental function, with a 52% reduction in the risk of decline on that measure. A pooled analysis of 1,402 patients from four Phase 3 studies of Amvuttra and Onpattro showed consistent effects in women and men across cardiac and neurological forms of the disease. For zilebesiran, a post hoc subgroup analysis from the Phase 2 KARDIA-3 study showed larger systolic blood pressure reductions in high-risk patients with uncontrolled hypertension on a diuretic and at least one other drug, with effects extending across day and night; these findings are exploratory, and the drug's value depends on the ongoing Phase 3 ZENITH cardiovascular outcomes trial.
Moderna Gets FDA Approvals for Updated COVID and First mRNA Flu Shots
Moderna received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines tailored to the latest SARS-CoV-2 subvariant, as well as mFlusiva, its first mRNA-based influenza vaccine for adults aged 50 and over. These approvals expand Moderna's respiratory vaccine portfolio and mark the first FDA-authorized mRNA flu shot for older adults. The company, a US-based biotechnology firm developing messenger RNA medicines, sees these approvals as reinforcing its regulatory momentum and diversifying its respiratory offerings against competitors like Pfizer and Novavax in COVID and Sanofi and GSK in flu. However, analysts note that respiratory shots still depend on annual uptake, pricing, and pharmacy stocking, so the key question is how far these launches reduce reliance on a narrow set of seasonal products.
Pfizer won FDA approval Thursday for its updated Comirnaty COVID vaccine, with deliveries starting immediately and doses expected in pharmacies and clinics within days. The vaccine, developed with BioNTech, is now limited to adults 65 and older and higher-risk patients aged 5 to 64, a much smaller market than the pandemic-era rollout. Comirnaty has distributed over five billion doses worldwide, but the new seasonal demand is uncertain. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine. Shares traded at $27.9079 on August 28, 5.27% above the GF Value estimate of $26.51, indicating a premium before uptake and reimbursement details emerge.
BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails
BioNTech shares tumbled 8% to $102.38 after the company terminated its Phase 2 colorectal cancer vaccine trial for futility, a setback that also dragged Moderna down 6% to $134.48 while Pfizer held nearly flat at $27.91. The trial, BNT122-01, tested the mRNA vaccine autogene cevumeran as a monotherapy in high-risk Stage II/III colorectal cancer patients, and an independent Data Safety Monitoring Board found a numerical imbalance in overall survival that made further continuation futile. The futility boundary was first crossed in October 2025, but the data were initially deemed too immature to halt the study. Moderna's recent melanoma vaccine success does not shield it from the read-across because colorectal cancer is immunologically cold, and BioNTech's monotherapy design was a harder hurdle than Moderna's checkpoint-combination approach. Separately, the FDA approved the 2026-2027 COVID-19 vaccine formula from Pfizer and BioNTech, but that seasonal approval is not enough to offset the loss of a flagship oncology asset for BioNTech, which still holds €16.6 billion in cash and securities.
FDA Approves Priovant's Lisraya for Dermatomyositis
Priovant Therapeutics, backed by Pfizer and Roivant Sciences, has received FDA approval for its lead asset, Lisraya (brepocitinib), for the treatment of dermatomyositis, a rare autoimmune disorder. The once-daily 30 mg pill is now available immediately in the U.S. as the first and only targeted therapy for this condition. The approval is based on data from the Phase 3 VALOR trial, which showed improvements across multiple disease areas as early as week four, sustained through the 52-week study. The TYK2/JAK1 inhibitor will be distributed through a limited network of specialty pharmacies, following a priority review granted in March with a target action date in Q3 2026.
The global cytotoxic drugs market is projected to grow from $16.21 billion in 2026 to $21.06 billion by 2031, at a compound annual growth rate of 5.37%, according to a new report from ResearchAndMarkets.com. Rising cancer incidence, earlier diagnosis, expanded reimbursement, and growing demand in emerging economies are driving the market. In 2025, the market was valued at $15.38 billion, with parenteral drugs holding a 68.87% share, while oral drugs are expected to grow faster at an 8.79% CAGR. Alkylating agents led with a 30.10% share in 2025, but antimetabolites are forecast to grow fastest at 7.02% CAGR. North America accounted for 42.15% of revenue in 2025, while Asia-Pacific is projected to grow at 10.07% CAGR, supported by China's approval of 228 drugs in 2024, 37% of which were antineoplastics. Key players include Pfizer, Roche, Novartis, AstraZeneca, and Sanofi.
Pfizer Vaccine Milestones Could Shift Investment Narrative
Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 had its Marketing Authorization Application validated by the European Medicines Agency based on Phase 3 trial data. These milestones highlight Pfizer's role in infectious disease prevention, with the Lyme vaccine potentially becoming a key proof point for its pipeline. However, unresolved legal and pricing pressures, including the Depo Provera settlement program, remain overhangs. Pfizer's narrative projects $54.9 billion in revenue and $9.2 billion in earnings by 2029, implying a 4.6% yearly revenue decline and a $1.7 billion earnings increase from $7.5 billion today, yielding a $29.19 fair value, a 4% upside to its current price. Some analysts assume revenue could fall to about US$50.6 billion by 2029, reinforcing concerns that pipeline wins may not fully offset pricing pressure and patent losses.
Pfizer and BioNTech Win FDA Approval for Updated COVID-19 Shot
Pfizer and BioNTech have received U.S. FDA approval for their updated mRNA COVID-19 vaccine, COMIRNATY XFG, for the 2026-27 season. The shot targets the XFG variant and is indicated for individuals aged five to 64 with at least one underlying condition that puts them at high risk for severe outcomes from the virus, as well as for all adults aged 65 and older.
Pfizer and Valneva Start EMA Review for Lyme Disease Vaccine
Pfizer and Valneva announced that the European Medicines Agency has validated the Marketing Authorization Application for their Lyme disease vaccine candidate, PF-07307405, initiating the regulatory assessment process for what could become a first-in-class vaccine for the disease in North America and Europe. The application is backed by Phase 3 efficacy data, with the companies highlighting an unmet medical need in Lyme disease prevention. This development is part of Pfizer's broader strategy to address widespread infectious diseases, complementing its existing vaccine portfolio. Investors should monitor the EMA's review milestones, including committee opinions and formal decisions expected into 2027, as well as any disclosures on manufacturing readiness and uptake expectations for the vaccine.
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
BridgeBio Pharma reported second-quarter revenues of $243.7 million, up 120% year over year and above the Zacks Consensus Estimate of $222.6 million, driven by Attruby U.S. product sales of $222.4 million, more than triple the $71.5 million from a year earlier. The company posted a net loss of 78 cents per share, wider than the expected 64-cent loss but improved from a 95-cent loss a year ago, as research and development expenses rose 34% to $149.4 million and selling, general and administrative expenses climbed 44% to $186.3 million. Management said Attruby's first-line share in ATTR-CM rose two to three percentage points in the quarter, while the pool of patients switching from Pfizer's Vyndaqel/Vyndamax has begun to normalize. BridgeBio ended June with $720.2 million in cash, cash equivalents and marketable securities, down from $940.2 million at the end of the prior quarter, but a $1 billion preferred equity financing that closed July 1 lifted the cash balance to about $1.7 billion. The company is preparing for three potential U.S. product launches over the next 12 months, including BBP-418 with an FDA decision date of November 27, 2026, encaleret under review for a May 8, 2027 decision, and infigratinib targeted for a potential early- to mid-2027 launch if approved.
Johnson & Johnson Appears Better Prepared for Patent Cliff Than Pfizer
Johnson & Johnson appears better prepared for its patent cliff than Pfizer, based on their latest results. J&J's Innovative Medicine sales rose 7.8% to $16.38 billion despite a 55% decline in Stelara revenue, helped by Tremfya sales jumping 72.5% to about $2 billion. The company raised its 2026 reported-sales guidance to a midpoint of $101.1 billion and increased adjusted EPS guidance by $0.13 to $11.68. Pfizer's revenue excluding Comirnaty and Paxlovid grew 5% operationally in fiscal Q2 2026, but total operational growth was only 1%, and the company recorded a GAAP net loss of $248 million. Pfizer expects about $9.7 billion in total net savings through 2029 from cost-realignment and manufacturing-optimization programs.
Pfizer's Turnaround Gains Traction but Patent Cliff Looms
Pfizer reported a 1% year-over-year operational increase in fiscal Q2 2026 revenue to $15.0 billion, while revenue excluding Comirnaty and Paxlovid grew 5% operationally, and management raised the midpoint of its full-year revenue guidance. Launched and acquired medicines generated $3.2 billion in quarterly revenue and grew 18% operationally, with Padcev revenue up 23% to $667 million and the Vyndaqel family up 8% to $1.76 billion. The company cut its 2026 COVID-19 revenue estimate to approximately $4 billion due to weaker PAXLOVID demand, and expanded its cost-savings target to about $5.7 billion in net savings by the end of 2026 and $6.7 billion through 2029. However, Pfizer expects an unfavorable revenue impact of approximately $1.1 billion in 2026 from recent and expected generic and biosimilar competition, with major products facing patent expirations between 2026 and 2030 including Eliquis, Ibrance, and Xtandi. Hedge fund ownership rose modestly from 81 in Q4 2025 to 83 in Q1 2026, according to Insider Monkey's database of 1,022 hedge funds.
Bristol Myers Raises 2026 Outlook on Eliquis Strength
Bristol Myers Squibb raised its full-year 2026 revenue guidance to $49-$50 billion, up from $46-$47.5 billion, after Eliquis sales grew 19% to $8.6 billion in the first half. The company now expects Eliquis revenue growth of 20-25% for the year, versus a prior 10-15% forecast, and legacy portfolio revenues to decline 4-6% instead of 12-16%. Eliquis, co-commercialized with Pfizer, posted 22% growth in the second quarter, helping offset generic erosion for Revlimid, Pomalyst, Sprycel and Abraxane. Management still expects Eliquis sales to decline by $1.5-$2 billion in 2027.
PWIN and PWINRMF funds benefit from healthcare stock surge
The Phillip World Innovation Fund, or PWIN, and the Phillip World Innovation Retirement Mutual Fund, or PWINRMF, have received a positive boost from the global rise in healthcare stocks, one of the three core investment themes the funds emphasize, alongside information technology, semiconductors, AI and data centers, and clean energy infrastructure. The S&P 500 Healthcare Index has risen 10.8% since the outbreak of conflict in the Middle East, calculated from the closing price on March 2, 2026, compared with the closing price on August 19, 2026, according to Bloomberg data. A specific positive factor came from late-stage trial results in patients with melanoma skin cancer, indicating that the use of Moderna's mRNA vaccine in combination with Merck's Keytruda produced positive outcomes. This sent Moderna's share price soaring by as much as 176% and lifted Merck's shares by 12% on August 19 alone. Other healthcare stocks such as Eli Lilly, Novartis, and Pfizer also saw significant gains.
Pfizer Targets 2028 Approval for Monthly Obesity Drug Berobenatide
Pfizer is advancing berobenatide, a long-acting GLP-1 receptor agonist acquired through its 2025 purchase of Metsera, as its lead candidate to compete in the obesity market projected to reach nearly $114 billion by 2030. The drug is in phase III development for chronic weight management and is designed to transition from weekly to monthly maintenance dosing, with phase IIb VESPER data showing meaningful weight loss and a favorable tolerability profile. Pfizer plans to start more than 20 obesity studies in 2026, including 10 phase III trials for berobenatide in obesity and related conditions such as knee osteoarthritis and obstructive sleep apnea, and is targeting the first potential approvals in 2028. The company is also evaluating berobenatide in combination with an ultra-long-acting amylin analog, PF'3945, in phase II studies with additional data expected later this year. Pfizer faces competition from Eli Lilly and Novo Nordisk, which dominate the market with Zepbound and Wegovy, as well as from Amgen, Roche, AstraZeneca, AbbVie, and smaller biotechs developing next-generation obesity treatments.
Pfizer and Valneva Lyme Disease Vaccine Application Validated by EMA
The European Medicines Agency has validated the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405, beginning its assessment of the submission. The application is based on efficacy of more than 70% observed in the Phase 3 VALOR trial, which enrolled 9,437 participants aged five and older across the U.S., Canada, and Europe, with no safety concerns identified. Pfizer's Chief Vaccines Officer Annaliesa Anderson said the vaccine could be the first of its kind in Europe, where Lyme disease affects more than 100,000 people annually and over 200 million live in risk areas. Valneva CEO Thomas Lingelbach called the acceptance a major milestone for the collaboration established in April 2020, under which Pfizer will exclusively manufacture and commercialize the vaccine if approved.
Nearly nine in ten EU4+UK hematologists now require longer-term efficacy data before referring patients with hemophilia A for gene therapy, according to new research from Spherix Global Insights. The 2026 Market Dynamix study of 160 hematologists across France, Germany, Italy, Spain, and the United Kingdom found that 89% of physicians need longer-term efficacy data, up 23 percentage points from 66% in 2025. Patient research shows 37% of 169 US patients with hemophilia A or B were considered good candidates for gene therapy but were not currently pursuing it, while 36% of hemophilia A patients and 24% of hemophilia B patients expressed strong interest. The findings come amid commercial setbacks including the discontinuation of BEQVEZ by Pfizer, withdrawal of ROCTAVIAN by BioMarin, and supply challenges for HEMGENIX by CSL Behring.
Valneva Reports First Half 2026 Results and Reaffirms Guidance
Valneva SE reported first half 2026 financial results with total product sales of €64.0 million and reaffirmed its full-year guidance of €135 to €150 million in product sales. The company posted a net loss of €63.3 million for the six months ended June 30, 2026, compared with a net loss of €20.8 million in the same period of 2025, reflecting lower gross margin due to lower sales and manufacturing volumes as well as one-off impacts on cost of goods sold, including IXCHIQ-related contract termination costs and inventory write-offs. Valneva's cash position stood at €121.5 million as of end June 2026, up from €109.7 million at December 31, 2025, supported by disciplined cash management and €37 million in gross proceeds from a reserved offering completed in the second quarter. The company also implemented a global restructuring program expected to have positive profit and loss and cash flow impacts in the second half of the year and beyond, including a workforce reduction and the agreed sale of its Nantes site in France for €6.2 million. Regulatory decisions for the Lyme disease vaccine candidate LB6V, partnered with Pfizer, are expected in the next twelve months, with Pfizer expressing optimism about obtaining registration.
Pfizer Q2 Earnings Call: Analysts Probe Pipeline, Dividend, and Guidance
Pfizer reported second-quarter results that beat analyst expectations, with revenue of $15.03 billion versus estimates of $14.4 billion and adjusted EPS of $0.77 versus $0.68. The company slightly lifted its full-year revenue guidance to $61.5 billion at the midpoint from $61 billion and reiterated adjusted EPS guidance of $2.90. During the earnings call, analysts questioned management on topics including the MEVPRO-1 prostate cancer trial, Padcev's growth outlook, mevrometostat's commercial potential, atirmociclib efficacy, and dividend sustainability. CEO Albert Bourla asserted the dividend would be maintained even under stressed scenarios and could grow post patent expirations.
Arbutus receives $178 million from Moderna settlement and plans up to $230 million shareholder return
Arbutus Biopharma reported second quarter 2026 financial results and announced it received a first payment of approximately $178 million in July from its $950 million settlement with Moderna, and expects to return up to approximately $230 million to shareholders through share repurchases starting in the third quarter. The company also filed three international patent infringement lawsuits against Pfizer and BioNTech related to its lipid nanoparticle technology, and achieved alignment with the FDA on a Phase 2b clinical trial design for its chronic hepatitis B drug candidate imdusiran. As of June 30, 2026, Arbutus held cash, cash equivalents and marketable securities of $92.6 million, and reported a net loss of $5.1 million for the quarter.
Pfizer agrees to $44 million Chantix class action settlement
Pfizer agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. The company also reported positive topline Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo, highlighting progress in its immunology pipeline. The settlement is relatively small compared to Pfizer's multi-billion-dollar revenue and helps clear a product-specific legal overhang. The LITFULO data supports Pfizer's strategy to expand in immunology and specialty therapies as it seeks to diversify beyond older products and upcoming patent expiries. Investors will be watching for global regulatory submissions for LITFULO in vitiligo and clearer disclosure on how dermatology and immunology launches contribute to the company's revised 2026 revenue guidance of US$60.5 billion to US$62.5 billion.
Pfizer raises 2026 revenue guidance while BioNTech cuts forecast and announces CEO transition
Pfizer raised its full-year 2026 revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion, while BioNTech cut its full-year 2026 revenue guidance to €1.6 billion to €1.9 billion from a prior range of €2.0 billion to €2.3 billion and announced that co-founder and CEO Prof. Ugur Sahin will step down to lead a new independent entity, with Guido Oelkers succeeding him as CEO by February 1, 2027. Pfizer reported Q2 2026 revenues of $15.0 billion, a 1% operational increase year-over-year, and adjusted diluted earnings per share of $0.77, while BioNTech's Q2 2026 revenues fell 59.5% year-over-year to €105.6 million and its IFRS net loss widened to €820.8 million. The European Commission authorized the companies' updated XFG-adapted COVID-19 vaccine on July 29. Pfizer also announced an expansion of productivity initiatives expected to yield $2.5 billion in additional savings between 2027 and 2029, while BioNTech maintains €16.6 billion in cash, cash equivalents, and security investments to fund its oncology pipeline.
Pfizer Rises Almost 7% After Q2 Beat and Raised Revenue Guidance
Pfizer stock has risen 6.9% since it reported second-quarter 2026 results on August 4, beating earnings and revenue estimates. The company raised the lower end of its 2026 revenue guidance to a range of $60.5 billion to $62.5 billion, up from $59.5 billion to $62.5 billion, while reaffirming adjusted earnings guidance of $2.80 to $3.00 per share, which now includes a 10-cent charge from a licensing deal with Innovent Biologics. Non-COVID product revenues grew 5% operationally excluding Comirnaty and Paxlovid, offsetting declining COVID product sales, which are now expected to total approximately $4 billion in 2026, down from a prior forecast of $5 billion. The company faces a loss of exclusivity cliff expected to reduce revenues by about $1.1 billion in 2026, but is advancing a pipeline in oncology and obesity, including the GLP-1 candidate berobenatide with potential approvals starting in 2028. Pfizer shares trade at a forward price-to-earnings ratio of 9.08, below the industry average of 18.53 and its five-year mean of 9.28, and offer a dividend yield of around 6.4%.
Eli Lilly, Novo Nordisk, and Pfizer lead healthcare news after quarterly results
Eli Lilly, Novo Nordisk, and Pfizer were among the notable healthcare companies reporting quarterly results this week. Eli Lilly posted better-than-expected second-quarter results driven by its GLP-1 drugs, with revenue of $23 billion beating consensus by $2.3 billion, and raised its full-year revenue guidance to a range of $85.0 billion to $87.0 billion, though the midpoint fell short of the $85.4 billion consensus. Novo Nordisk lifted its full-year outlook for the second time this year on GLP-1 strength, now expecting sales and operating profit to decline by no more than 6% at constant exchange rates, but its U.S.-listed shares fell as much as 6%. Pfizer topped second-quarter expectations with adjusted earnings per share of $0.77 and revenue of $15.03 billion, and raised its full-year revenue guidance by $500 million at the midpoint to $60.5 billion to $62.5 billion. Merck also reported better-than-expected second-quarter results and raised its full-year revenue guidance to $66.3 billion to $67.3 billion, but lowered its adjusted earnings per share forecast to $2.66 to $2.76, below the $2.76 consensus, due to charges from its Terns acquisition. Bristol-Myers Squibb fell after a Reuters report said there are no discussions with AstraZeneca about a potential deal, contradicting earlier reports of preliminary merger talks. Integer Holdings agreed to be acquired by KKR in an all-cash deal valued at approximately $5.7 billion, with stockholders receiving $127.00 per share. The S&P 500 Health Care Index Sector gained 1.92% during the week, with Charles River Laboratories and Veeva Systems among the top gainers, while DaVita and Insulet were among the top losers.
95% of healthcare firms beat EPS estimates this week
Twenty-one out of 22 healthcare companies that reported quarterly earnings this week delivered better-than-expected earnings per share, with Pfizer, Merck, and Eli Lilly among the major names topping Wall Street forecasts. Pfizer posted adjusted EPS of $0.77 on revenue of $15.03 billion and raised its full-year revenue guidance by $500 million at the midpoint to a range of $60.5 billion to $62.5 billion. Merck reported an adjusted loss of $0.13 per share while revenue rose 5.1% year over year to $16.61 billion, driven by Keytruda sales of $8.4 billion. Eli Lilly’s adjusted EPS jumped roughly 33% to $8.38 on revenue of $23 billion, powered by its GLP-1 portfolio including Zepbound and Mounjaro. Vertex Pharmaceuticals was the only firm to miss earnings estimates, while Zoetis and STERIS fell short on revenue.
USA